BIOLASE, INC. Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows, 13 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-08-12: Reporting owner OLoughlin Kathleen T; Form 4; Security Stock Appreciation Right; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-08-12: Reporting owner Somerman Martha J. DDS, PhD; Form 4; Security Stock Appreciation Right; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-08-12: Reporting owner Summerhays Carol Gomez DDS; Form 4; Security Stock Appreciation Right; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-08-11: Reporting owner BEAVER JOHN R; Form 4; Security Stock Appreciation Right; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-08-12 | OLoughlin Kathleen T Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +98,955 98,955 owned after | $0.63 exercise price | 2021-08-26 | |
| 2021-08-12 | Somerman Martha J. DDS, PhD Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +98,955 98,955 owned after | $0.63 exercise price | 2021-08-23 | |
| 2021-08-12 | Summerhays Carol Gomez DDS Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +98,955 98,955 owned after | $0.63 exercise price | 2021-08-23 | |
| 2021-08-11 | BEAVER JOHN R Director, Officer (President & CEO) | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +220,000 220,000 owned after | $0.63 exercise price | 2021-08-13 | |
| 2021-06-11 | DiTolla Michael Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104,603 104,603 owned after | $0.84 exercise price | 2021-06-14 | |
| 2021-06-11 | Lanman Richard B. Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104,603 104,603 owned after | $0.84 exercise price | 2021-06-14 | |
| 2021-06-11 | Wagner Elaine C Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104,603 104,603 owned after | $0.84 exercise price | 2021-06-14 | |
| 2021-06-11 | Sato Garrett Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +110,888 110,888 owned after | $0.84 exercise price | 2021-06-14 | |
| 2021-06-11 | ROPER JESS Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +111,337 111,337 owned after | $0.84 exercise price | 2021-06-14 | |
| 2021-06-11 | LORD JONATHAN T MD Director | 4 | Stock Appreciation Right Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +189,902 189,902 owned after | $0.84 exercise price | 2021-06-14 | |
| 2017-12-05 | LORD JONATHAN T MD Director | 4 | Subscription Rights (Right to Buy) Derivative · Direct | X Exercise of in-the-money or at-the-money derivative security | −100,000 0 owned after | $0.46 exercise price | 2017-12-06 | |
| 2017-12-05 | Flynn Harold C Jr. Director, Officer (President and CEO) | 4 | Subscription Rights (Right to Buy) Derivative · Indirect · By Trust | X Exercise of in-the-money or at-the-money derivative security | −65,870 0 owned after | $0.46 exercise price | 2017-12-06 | |
| 2017-12-05 | TALEVICH JAMES R Director | 4 | Subscription Rights (Right to Buy) Derivative · Direct | X Exercise of in-the-money or at-the-money derivative security | −3,189 0 owned after | $0.46 exercise price | 2017-12-06 |